What can 45,000 exomes tell you about GWAS and core genes? Come ask the always classy @PeterDornbos from 2-3PM at #ASHG19 poster 2804

Actually , I can't promise that. But we can discuss anything related to the @T2DKP , @KPortalNetwork , or our recent nature paper on large-scale exome analysis

No longer content with simply being thrilled by all the #ASHG19 science?I'll be off the chain at the @BroadGenomics booth 714 from 10-11.

Interested in scientific software & methods for moving for complex disease associations to targets? Come talk with Jason Flannick @jaflannick at the @BroadGenomics booth tomorrow👇

Is a p=0.02 association real or not? It depends on the gene. See Lokendra Thakur talk about our method for gene prior calculations at #ASHG19 Room 371A/4:45pm

If you are only half interested, just come for the snacks!

I will be speaking about the computational methods and visualizations we are developing

Want to learn more about how to manage all of the datasets needed to translate from association to function? Come to our @T2DKP #ASHG19 ancillary event at the Marriott Marquis Tanglewood room at 12:45.

The @T2DKP is hosting an ancillary event at #ASHG19 Foundational Resources for Translating Genetic Associations to Function & Targets! Come join the discussion & demo, Wednesday, Oct. 16, 12:45. Details 👇

Looking forward to #ASHG19. If you are attending and interested in postdoc opportunities in exome analysis or integrative computational genomics, message me and we can chat about opportunities in https://t.co/7Ha6oaHuKD.

And (2) solid evidence that toxicity can be predicted as well (well-done analysis in this one as well)

In particular (1) coding GWAS variants seem to increase likelihood of success even more than the two-fold reported earlier for arbitrary GWAS

Was reviewing some work on genetics + drug targets and found these to be of interest: https://t.co/qo9bOStzQF and

Our new study of coding variants and T2D shows that rare variants contribute less to T2D than we thought a decade ago, but may be more useful than we thought three years ago: https://t.co/CHwKA9IR8X @T2DKP @npburtt

New analyses on the genomic architecture of T2D & contribution of rare variation, with lessons for rare variant studies. Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls @nature https://t.co/KgBkD7XrIX Congrats J Flannick @markmccarthyoxf @npburtt et al!